RxDoctor Payments Data

Judy Hu, MD

Dermatology · Brentwood, TNNPI 1205897840

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,486 of the $5,077 with a category attached, or 88.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$5,077in general payments, 2019–2025

Across 239 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$867
  • AbbVie$714
  • Sanofi$457
  • Regeneron Healthcare Solutions, Inc.$309
  • Sun Pharmaceutical Industries Inc.$248
  • plus $1K from 19 others
$668,377in research payments, 2019–2025

Across 62 payments — averaging $10,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$352K
  • Takeda Pharmaceuticals U.S.A., Inc.$273K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Hoffmann-la Roche Limited$15K
  • Eli Lilly$11K

What the payments were for

  • Food & beverage$4,48688%
  • Education$59112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,077 in reported general payments places this provider in the 60th percentile of 209 dermatology providers in Tennessee.

See all dermatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$182,881
Medicare patients
458
Services billed
3,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$78,348
Desonide21$1,364
Clobetasol Propionate18$665
Betamethasone Valerate20$637
Triamcinolone Acetonide57$531
Ciclopirox12$525
Metronidazole15$464
Doxycycline Hyclate37$416
Ketoconazole39$389
Mupirocin37$254
Cephalexin16$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$190$78,34816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 209 dermatology providers in Tennessee.

Other dermatology in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →